The Bull Case For BeOne Medicines (ONC) Could Change Following Strong Sonrotoclax B‑Cell Cancer Data - Learn Why

• In December 2025, BeOne Medicines reported new clinical data at the ASH meeting showing its investigational BCL2 inhibitor sonrotoclax delivered meaningful benefit in difficult-to-treat B-cell malignancies, including relapsed or refractory mantle cell lymphoma with over half of patients responding in a Phase 1/2 study under U.S. FDA Priority Review for potential accelerated approval.
• The findings, including rapid and sustained undetectable minimal residual disease in treatment‑naive chronic lymphocytic leukemia and consistent responses in high‑risk subgroups, reinforce sonrotoclax’s potential to become a foundational therapy across multiple B‑cell cancers.
• Next, we’ll examine how sonrotoclax’s Priority Review status and early evidence of durable responses could reshape BeOne Medicines’ investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 36 companies in the world exploring or producing it. Find the list for free.

BeOne Medicines Investment Narrative Recap

To own BeOne Medicines, you need to believe sonrotoclax can evolve into a meaningful second pillar alongside BRUKINSA, reducing single‑product dependence. The new ASH data, under U.S. FDA Priority Review, strengthens the near term approval catalyst but does not remove core risks around oncology competition and pricing pressure in key markets.

The most directly relevant recent announcement is the FDA’s November 2025 acceptance of BeOne’s NDA for sonrotoclax in relapsed or refractory mantle cell lymphoma with Priority Review and planned Project Orbis participation. Together with the ASH efficacy and tolerability data, this filing milestone frames sonrotoclax as a potential near term contributor to the pipeline inflection that management and analysts have been highlighting through 2026.

However, while sonrotoclax could broaden BeOne’s oncology mix, investors should also be aware that...

Read the full narrative on BeOne Medicines (it's free!)

BeOne Medicines' narrative projects $7.6 billion revenue and $1.3 billion earnings by 2028. This requires 18.6% yearly revenue growth and about a $1.48 billion earnings increase from -$177.6 million today.

Uncover how BeOne Medicines' forecasts yield a $401.52 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$250 to about US$738 per share, reflecting very different expectations. Set against this, the sonrotoclax Priority Review catalyst sits alongside persistent competitive and pricing risks that could influence how those views evolve, so it is worth weighing several perspectives before deciding what you think the company is worth.

Explore 6 other fair value estimates on BeOne Medicines - why the stock might be worth over 2x more than the current price!

Build Your Own BeOne Medicines Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BeOne Medicines research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BeOne Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BeOne Medicines' overall financial health at a glance.

Seeking Other Investments?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find companies with promising cash flow potential yet trading below their fair value.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com